These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 28665401)

  • 1. PD-L1 and IAPs co-operate to protect tumors from cytotoxic lymphocyte-derived TNF.
    Kearney CJ; Lalaoui N; Freeman AJ; Ramsbottom KM; Silke J; Oliaro J
    Cell Death Differ; 2017 Oct; 24(10):1705-1716. PubMed ID: 28665401
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Smac mimetic Birinapant induces apoptosis and enhances TRAIL potency in inflammatory breast cancer cells in an IAP-dependent and TNF-α-independent mechanism.
    Allensworth JL; Sauer SJ; Lyerly HK; Morse MA; Devi GR
    Breast Cancer Res Treat; 2013 Jan; 137(2):359-71. PubMed ID: 23225169
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Birinapant (TL32711), a bivalent SMAC mimetic, targets TRAF2-associated cIAPs, abrogates TNF-induced NF-κB activation, and is active in patient-derived xenograft models.
    Benetatos CA; Mitsuuchi Y; Burns JM; Neiman EM; Condon SM; Yu G; Seipel ME; Kapoor GS; Laporte MG; Rippin SR; Deng Y; Hendi MS; Tirunahari PK; Lee YH; Haimowitz T; Alexander MD; Graham MA; Weng D; Shi Y; McKinlay MA; Chunduru SK
    Mol Cancer Ther; 2014 Apr; 13(4):867-79. PubMed ID: 24563541
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activation of concurrent apoptosis and necroptosis by SMAC mimetics for the treatment of refractory and relapsed ALL.
    McComb S; Aguadé-Gorgorió J; Harder L; Marovca B; Cario G; Eckert C; Schrappe M; Stanulla M; von Stackelberg A; Bourquin JP; Bornhauser BC
    Sci Transl Med; 2016 May; 8(339):339ra70. PubMed ID: 27194728
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The novel SMAC mimetic birinapant exhibits potent activity against human melanoma cells.
    Krepler C; Chunduru SK; Halloran MB; He X; Xiao M; Vultur A; Villanueva J; Mitsuuchi Y; Neiman EM; Benetatos C; Nathanson KL; Amaravadi RK; Pehamberger H; McKinlay M; Herlyn M
    Clin Cancer Res; 2013 Apr; 19(7):1784-94. PubMed ID: 23403634
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antagonism of IAPs Enhances CAR T-cell Efficacy.
    Michie J; Beavis PA; Freeman AJ; Vervoort SJ; Ramsbottom KM; Narasimhan V; Lelliott EJ; Lalaoui N; Ramsay RG; Johnstone RW; Silke J; Darcy PK; Voskoboinik I; Kearney CJ; Oliaro J
    Cancer Immunol Res; 2019 Feb; 7(2):183-192. PubMed ID: 30651288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IAP antagonists Birinapant and AT-406 efficiently synergise with either TRAIL, BRAF, or BCL-2 inhibitors to sensitise BRAFV600E colorectal tumour cells to apoptosis.
    Perimenis P; Galaris A; Voulgari A; Prassa M; Pintzas A
    BMC Cancer; 2016 Aug; 16():624. PubMed ID: 27520705
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Apoptosis repressor with caspase recruitment domain modulates second mitochondrial-derived activator of caspases mimetic-induced cell death through BIRC2/MAP3K14 signalling in acute myeloid leukaemia.
    Mak PY; Mak DH; Ruvolo V; Jacamo R; Kornblau SM; Kantarjian H; Andreeff M; Carter BZ
    Br J Haematol; 2014 Nov; 167(3):376-84. PubMed ID: 25079338
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacodynamic markers and clinical results from the phase 2 study of the SMAC mimetic birinapant in women with relapsed platinum-resistant or -refractory epithelial ovarian cancer.
    Noonan AM; Bunch KP; Chen JQ; Herrmann MA; Lee JM; Kohn EC; O'Sullivan CC; Jordan E; Houston N; Takebe N; Kinders RJ; Cao L; Peer CJ; Figg WD; Annunziata CM
    Cancer; 2016 Feb; 122(4):588-597. PubMed ID: 26566079
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The caspase-8 inhibitor emricasan combines with the SMAC mimetic birinapant to induce necroptosis and treat acute myeloid leukemia.
    Brumatti G; Ma C; Lalaoui N; Nguyen NY; Navarro M; Tanzer MC; Richmond J; Ghisi M; Salmon JM; Silke N; Pomilio G; Glaser SP; de Valle E; Gugasyan R; Gurthridge MA; Condon SM; Johnstone RW; Lock R; Salvesen G; Wei A; Vaux DL; Ekert PG; Silke J
    Sci Transl Med; 2016 May; 8(339):339ra69. PubMed ID: 27194727
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SMAC mimetic birinapant inhibits hepatocellular carcinoma growth by activating the cIAP1/TRAF3 signaling pathway.
    Ding J; Qin D; Zhang Y; Li Q; Li Y; Li J
    Mol Med Rep; 2020 Mar; 21(3):1251-1257. PubMed ID: 31922244
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Eliminating hepatitis B by antagonizing cellular inhibitors of apoptosis.
    Ebert G; Allison C; Preston S; Cooney J; Toe JG; Stutz MD; Ojaimi S; Baschuk N; Nachbur U; Torresi J; Silke J; Begley CG; Pellegrini M
    Proc Natl Acad Sci U S A; 2015 May; 112(18):5803-8. PubMed ID: 25902530
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A small molecule Smac-mimic compound induces apoptosis and sensitizes TRAIL- and etoposide-induced apoptosis in breast cancer cells.
    Bockbrader KM; Tan M; Sun Y
    Oncogene; 2005 Nov; 24(49):7381-8. PubMed ID: 16044155
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The SMAC mimetic birinapant attenuates lipopolysaccharide-induced liver injury by inhibiting the tumor necrosis factor receptor-associated factor 3 degradation in Kupffer cells.
    Liu H; Liao R; He K; Zhu X; Li P; Gong J
    Immunol Lett; 2017 May; 185():79-83. PubMed ID: 28286228
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A nanodrug incorporating siRNA PD-L1 and Birinapant for enhancing tumor immunotherapy.
    Gong T; Cai Y; Sun F; Chen J; Su Z; Shuai X; Shan H
    Biomater Sci; 2021 Nov; 9(23):8007-8018. PubMed ID: 34714906
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SMAC Mimetic/IAP Inhibitor Birinapant Enhances Radiosensitivity of Glioblastoma Multiforme.
    Cerna D; Lim B; Adelabu Y; Yoo S; Carter D; Fahim A; Mitsuuchi Y; Teicher BA; Bernhard E; Coleman CN; Takebe N; Ahmed MM
    Radiat Res; 2021 Jun; 195(6):549-560. PubMed ID: 33826739
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biomarker profile for prediction of response to SMAC mimetic monotherapy in pediatric precursor B-cell acute lymphoblastic leukemia.
    Zinngrebe J; Schlichtig F; Kraus JM; Meyer M; Boldrin E; Kestler HA; Meyer LH; Fischer-Posovszky P; Debatin KM
    Int J Cancer; 2020 Jun; 146(11):3219-3231. PubMed ID: 31749151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Phase I Study of the SMAC-Mimetic Birinapant in Adults with Refractory Solid Tumors or Lymphoma.
    Amaravadi RK; Schilder RJ; Martin LP; Levin M; Graham MA; Weng DE; Adjei AA
    Mol Cancer Ther; 2015 Nov; 14(11):2569-75. PubMed ID: 26333381
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patient-derived glioblastoma cells show significant heterogeneity in treatment responses to the inhibitor-of-apoptosis-protein antagonist birinapant.
    Zakaria Z; Tivnan A; Flanagan L; Murray DW; Salvucci M; Stringer BW; Day BW; Boyd AW; Kögel D; Rehm M; O'Brien DF; Byrne AT; Prehn JH
    Br J Cancer; 2016 Jan; 114(2):188-98. PubMed ID: 26657652
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting p38 or MK2 Enhances the Anti-Leukemic Activity of Smac-Mimetics.
    Lalaoui N; Hänggi K; Brumatti G; Chau D; Nguyen NY; Vasilikos L; Spilgies LM; Heckmann DA; Ma C; Ghisi M; Salmon JM; Matthews GM; de Valle E; Moujalled DM; Menon MB; Spall SK; Glaser SP; Richmond J; Lock RB; Condon SM; Gugasyan R; Gaestel M; Guthridge M; Johnstone RW; Munoz L; Wei A; Ekert PG; Vaux DL; Wong WW; Silke J
    Cancer Cell; 2016 Feb; 29(2):145-58. PubMed ID: 26859455
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.